Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.
-
Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis
Voltaren Arthritis Pain will donate 100% of pre-order profits up to $100k to the Arthritis Foundation
-
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks
-
Update on GSK actions to support the global response to COVID-19
As a leader in science and innovation, we are contributing to the fight against COVID-19 with our advanced vaccine adjuvant systems.
-
GSK appoints Charles Bancroft to the Board as a Non-Executive Director
GlaxoSmithKline plc today announced that Charles Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
-
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV
ViiV Healthcare, today announced that Health Canada has approved CABENUVA.
-
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
ViiV Healthcare presents positive long-term data from phase III study
-
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
ViiV Healthcare presents positive 48-week data from phase III study
-
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
-
FDA approves GSK’s Advil Dual Action with Acetaminophen for over-the-counter use in the United States
GSK announced that the U.S. FDA has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief.
-
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV
ViiV Healthcare initiates study with the University of South Carolina
-
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
-
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
U.S. FDA accepts GSK’s sNDA application for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
-
FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States
U.S. FDA has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an OTC product
-
GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)
Total EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1% CER
-
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
-
GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development
GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.
-
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients
-
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.
-
Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)
GlaxoSmithKline plc today announced that Deborah Waterhouse, CEO of ViiV Healthcare, will join GSK’s Corporate Executive Team